Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

NCT00676663 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Estrogen Receptor-Positive Breast Cancer
Breast Cancer, Estrogen Receptor-Positive
ER+ Breast Cancer

Interventions

DRUG: entinostat
DRUG: exemestane
DRUG: Placebo

Sponsor

Syndax Pharmaceuticals